Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 980 vs Trastuzumab in HER2+ Early Breast Cancer
NCT01901146Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2013
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of abp 980 in HER2-positive breast cancer, sponsored by Amgen. Started Apr 2013; status: completed.
02
Drugs
abp 980
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01901146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01901146.